Shares of Scancell Holdings plc (LON:SCLP – Get Free Report) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 9.89 and traded as low as GBX 9.60. Scancell shares last traded at GBX 9.88, with a volume of 1,407,764 shares traded.
Scancell Stock Performance
The firm’s 50 day moving average price is GBX 9.86 and its two-hundred day moving average price is GBX 9.89. The firm has a market cap of £102.48 million, a PE ratio of -7.84 and a beta of 0.35. The company has a debt-to-equity ratio of -566.79, a quick ratio of 13.01 and a current ratio of 3.42.
Scancell Company Profile
Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.
Featured Articles
- Five stocks we like better than Scancell
- Do not delete, read immediately
- INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
- Can Any Expenses Be Deducted From Capital Gains Tax?
- Do you know what Amazon is planning for January 1?
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
